Agilent Technologies and Roche Establish Agreement to Provide Continued Service and Support to Roche NimbleGen Microarray Customers

Agilent Technologies Inc. (NYSE: A) and Roche (SIX: RO, ROG) (OTCQX:
RHHBY) today announced the signing of an exclusive agreement to provide
continued service to NimbleGen microarray customers as Roche phases out
its NimbleGen array production and services.

Researchers using NimbleGen microarrays for all applications, including
comparative genomic hybridization, chromatin
immunoprecipitation-on-chip, DNA methylation and gene expression can
transition to Agilent arrays, effective immediately, with minimal
disruption. The similarities of the technologies and products from both
companies provide an optimal transition path and the ability to run
Agilent microarrays on the NimbleGen MS 200 Microarray Scanner.

“This global collaboration provides our customers with a confident and
straightforward solution to move from NimbleGen to Agilent microarrays,”
said Dan Zabrowski, head of Roche Applied Science.

“With Agilent as a leading global supplier of microarray technology, we
are convinced researchers will be provided with the highest
compatibility to NimbleGen products and services, and believe that they
will continue to receive the exceptional service and support they have
come to expect.”

“We are working closely with Roche to help customers make the transition
to Agilent microarray products,” said Robert Schueren, vice president
and general manager of Agilent’s Genomics Systems Division. “Our field
service personnel are working directly with individual researchers to
help convert their NimbleGen designs, and they will continue to provide
enhanced service and support throughout the transition period and
beyond. Additionally, Agilent is also enabling customers to read their
arrays on NimbleGen scanners, eliminating the need to invest in capital
equipment.”

Headquartered in Basel, Switzerland, Roche is a leader in
research-focused healthcare with combined strengths in pharmaceuticals
and diagnostics. Roche is the world’s largest biotech company with truly
differentiated medicines in oncology, virology, inflammation, metabolism
and CNS. Roche is also the world leader in in-vitro diagnostics,
tissue-based cancer diagnostics and a pioneer in diabetes management.
Roche’s personalized healthcare strategy aims at providing medicines and
diagnostic tools that enable tangible improvements in the health,
quality of life and survival of patients. In 2011, Roche had over 80,000
employees worldwide and invested over 8 billion Swiss francs in R&D. The
Group posted sales of 42.5 billion Swiss francs. Genentech, United
States, is a wholly owned member of the Roche Group. Roche has a
majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement
company and a technology leader in chemical analysis, life sciences,
diagnostics, electronics and communications. The company’s 20,000
employees serve customers in more than 100 countries. Agilent had net
revenues of $6.6 billion in fiscal 2011. Information about Agilent is
available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive
news is available at www.agilent.com/go/news.